158 related articles for article (PubMed ID: 26253444)
1. Putaminal serotonergic innervation: monitoring dyskinesia risk in Parkinson disease.
Lee JY; Seo S; Lee JS; Kim HJ; Kim YK; Jeon BS
Neurology; 2015 Sep; 85(10):853-60. PubMed ID: 26253444
[TBL] [Abstract][Full Text] [Related]
2. Serotonin-to-dopamine transporter ratios in Parkinson disease: Relevance for dyskinesias.
Roussakis AA; Politis M; Towey D; Piccini P
Neurology; 2016 Mar; 86(12):1152-8. PubMed ID: 26920358
[TBL] [Abstract][Full Text] [Related]
3. An FP-CIT PET comparison of the difference in dopaminergic neuronal loss in subtypes of early Parkinson's disease.
Song IU; Chung YA; Oh JK; Chung SW
Acta Radiol; 2014 Apr; 55(3):366-71. PubMed ID: 23943629
[TBL] [Abstract][Full Text] [Related]
4. Chronic motor cortex stimulation in patients with advanced Parkinson's disease and effects on striatal dopaminergic transmission as assessed by 123I-FP-CIT SPECT: a preliminary report.
Di Giuda D; Calcagni ML; Totaro M; Cocciolillo F; Piano C; Soleti F; Fasano A; Cioni B; Bentivoglio AR; Giordano A
Nucl Med Commun; 2012 Sep; 33(9):933-40. PubMed ID: 22735298
[TBL] [Abstract][Full Text] [Related]
5. Serotonin/dopamine transporter ratio as a predictor of L-dopa-induced dyskinesia.
Huot P; Hutchison WD
Neurology; 2015 Sep; 85(10):840-1. PubMed ID: 26253446
[No Abstract] [Full Text] [Related]
6. Serotonergic System Impacts Levodopa Response in Early Parkinson's and Future Risk of Dyskinesia.
Fu JF; Matarazzo M; McKenzie J; Neilson N; Vafai N; Dinelle K; Felicio AC; McKeown MJ; Stoessl AJ; Sossi V
Mov Disord; 2021 Feb; 36(2):389-397. PubMed ID: 33090574
[TBL] [Abstract][Full Text] [Related]
7. PET demonstrates reduced dopamine transporter expression in PD with dyskinesias.
Troiano AR; de la Fuente-Fernandez R; Sossi V; Schulzer M; Mak E; Ruth TJ; Stoessl AJ
Neurology; 2009 Apr; 72(14):1211-6. PubMed ID: 19020294
[TBL] [Abstract][Full Text] [Related]
8. Uneven age effects of [(18)F]FP-CIT binding in the striatum of Parkinson's disease.
Lee CS; Kim SJ; Oh SJ; Kim HO; Yun SC; Doudet D; Kim JS
Ann Nucl Med; 2014 Nov; 28(9):874-9. PubMed ID: 25008292
[TBL] [Abstract][Full Text] [Related]
9. Imaging in Parkinson's disease: the role of monoamines in behavior.
Brooks DJ; Piccini P
Biol Psychiatry; 2006 May; 59(10):908-18. PubMed ID: 16581032
[TBL] [Abstract][Full Text] [Related]
10. Correlating Parkinson's disease motor symptoms with three-dimensional [(18)F]FP-CIT PET.
Chung M; Park YS; Kim JS; Kim YJ; Ma HI; Jang SJ; Huh R; Kim HS; Kim WC
Jpn J Radiol; 2015 Oct; 33(10):609-18. PubMed ID: 25952404
[TBL] [Abstract][Full Text] [Related]
11. Serotonergic mechanisms responsible for levodopa-induced dyskinesias in Parkinson's disease patients.
Politis M; Wu K; Loane C; Brooks DJ; Kiferle L; Turkheimer FE; Bain P; Molloy S; Piccini P
J Clin Invest; 2014 Mar; 124(3):1340-9. PubMed ID: 24531549
[TBL] [Abstract][Full Text] [Related]
12. Serotonergic markers in Parkinson's disease and levodopa-induced dyskinesias.
Cheshire P; Ayton S; Bertram KL; Ling H; Li A; McLean C; Halliday GM; O'Sullivan SS; Revesz T; Finkelstein DI; Storey E; Williams DR
Mov Disord; 2015 May; 30(6):796-804. PubMed ID: 25649148
[TBL] [Abstract][Full Text] [Related]
13. Right putamen and age are the most discriminant features to diagnose Parkinson's disease by using
Cascianelli S; Tranfaglia C; Fravolini ML; Bianconi F; Minestrini M; Nuvoli S; Tambasco N; Dottorini ME; Palumbo B
Hell J Nucl Med; 2017; 20 Suppl():165. PubMed ID: 29324935
[TBL] [Abstract][Full Text] [Related]
14. The role of pallidal serotonergic function in Parkinson's disease dyskinesias: a positron emission tomography study.
Smith R; Wu K; Hart T; Loane C; Brooks DJ; Björklund A; Odin P; Piccini P; Politis M
Neurobiol Aging; 2015 Apr; 36(4):1736-1742. PubMed ID: 25649022
[TBL] [Abstract][Full Text] [Related]
15. Serial I-123-FP-CIT SPECT Image Findings of Parkinson's Disease Patients With Levodopa-Induced Dyskinesia.
Jeong EH; Sunwoo MK; Song YS
Front Neurol; 2018; 9():1133. PubMed ID: 30619078
[No Abstract] [Full Text] [Related]
16. The prominent role of serotonergic degeneration in apathy, anxiety and depression in de novo Parkinson's disease.
Maillet A; Krack P; Lhommée E; Météreau E; Klinger H; Favre E; Le Bars D; Schmitt E; Bichon A; Pelissier P; Fraix V; Castrioto A; Sgambato-Faure V; Broussolle E; Tremblay L; Thobois S
Brain; 2016 Sep; 139(Pt 9):2486-502. PubMed ID: 27538418
[TBL] [Abstract][Full Text] [Related]
17. Putaminal dopamine turnover in de novo Parkinson disease predicts later motor complications.
Löhle M; Mende J; Wolz M; Beuthien-Baumann B; Oehme L; van den Hoff J; Kotzerke J; Reichmann H; Storch A
Neurology; 2016 Jan; 86(3):231-40. PubMed ID: 26718573
[TBL] [Abstract][Full Text] [Related]
18. 123I-FP-CIT SPECT imaging of dopamine transporters in patients with cerebrovascular disease and clinical diagnosis of vascular parkinsonism.
Lorberboym M; Djaldetti R; Melamed E; Sadeh M; Lampl Y
J Nucl Med; 2004 Oct; 45(10):1688-93. PubMed ID: 15471834
[TBL] [Abstract][Full Text] [Related]
19. Iodine-123-N-omega-fluoropropyl-2beta-carbomethoxy-3beta-(4-iod ophenyl)tropane SPECT in healthy controls and early-stage, drug-naive Parkinson's disease.
Tissingh G; Booij J; Bergmans P; Winogrodzka A; Janssen AG; van Royen EA; Stoof JC; Wolters EC
J Nucl Med; 1998 Jul; 39(7):1143-8. PubMed ID: 9669384
[TBL] [Abstract][Full Text] [Related]
20. Dopamine transporter availability in motor subtypes of de novo drug-naïve Parkinson's disease.
Moccia M; Pappatà S; Picillo M; Erro R; Coda AR; Longo K; Vitale C; Amboni M; Brunetti A; Capo G; Salvatore M; Barone P; Pellecchia MT
J Neurol; 2014 Nov; 261(11):2112-8. PubMed ID: 25119838
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
